BMY Bristol-Myers Squibb Company
Trend channel, buy level and 3-month target. Information only, not financial advice.
Inside the channel · 12-month channel rising
Price is between the lines.
- 12-month channel
- US$56.55 – US$72.01 · rising, +30% a year
- Price in channel
- 39% (0% = floor, 100% = ceiling)
- Ceiling overhead
- US$71.96
- Turns bearish below
- US$56.52
Price history, with the path projected 3 months forward
Updated 11:56 PM ET (12 h ago)
- Daily close
- Upper trend line (12 months)
- Lower trend line (12 months)
- The same lines over the last 12 months
- Dashed after today: projected 3 months
- Our buy
- Our target
Suggested path
Buy at or below
US$60.88
level as at 8 Nov 2026
Our target
US$68.18
by 27 Dec 2026
Projected move
12.0%
gross, before costs
Price is between our buy and target.
Target: BMY's usual move size (12.0%), the best return per day on this path.
This move size: reached in 19% of 21 past stretches, typically in 72 days. (0.17% per day)
7 settled calls · 3 reached target (42.9%) · average best move 4.8%. See the full record.
- Upper line touches
- 5
- Lower line touches
- 4
- Fit confidence
- 76%
- Fitted
- 1 Nov 2026
Company information
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Christopher Boerner
- Employees
- 32,500
- Country
- US
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$115.76B
- Enterprise value
- —
- Beta
- 0.23
- Avg volume
- 11.78M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 42.52-68.64
- Exchange
- NYSE
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.